4 U.S. IPOs Planned For The Week Of July 30

|
 |  Includes: ELOQ, GMED, LGZ, NGVC, STML
by: Renaissance Capital IPO Research

The following IPOs are expected to price this week:

Eloqua (NASDAQ:ELOQ), which provides on-demand software to automate marketing and sales initiatives, plans to raise $84 million by offering 8.0 million shares at a price range of $9.50 to $11.50. At the midpoint of the proposed range, Eloqua would command a market value of $401 million. Eloqua, which was founded in 1999, booked $85 million in sales over the last 12 months. The Vienna, VA-based company plans to list on the NASDAQ under the symbol ELOQ. J.P. Morgan and Deutsche Bank Securities are the joint bookrunners on the deal.

Globus Medical (NYSE:GMED), which sells spine implants to hospitals for use in surgical procedures, plans to raise $200 million by offering 11.8 million shares at a price range of $16.00 to $18.00. At the midpoint of the proposed range, Globus Medical would command a market value of $1.6 billion. Globus Medical, which was founded in 2003, booked $348 million in sales over the last 12 months. The Audubon, PA-based company plans to list on the NYSE under the symbol GMED. BofA Merrill Lynch, Goldman Sachs, Piper Jaffray and Leerink Swann are the joint bookrunners on the deal.

LegalZoom.com (NYSE:LGZ), a provider of online legal services to consumers and small businesses in the U.S., plans to raise $88 million by offering 8.0 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, LegalZoom.com would command a market value of $483 million. LegalZoom.com, which was founded in 1999, booked $165 million in sales over the last 12 months. The Glendale, CA-based company plans to list on the NYSE under the symbol LGZ. Morgan Stanley and BofA Merrill Lynch are the joint bookrunners on the deal.

Stemline Therapeutics (NASDAQ:STML), a biotech developing treatments that target cancer stem cells and tumor bulk, plans to raise $42 million by offering 3.5 million shares at a price range of $11.00 to $13.00. At the midpoint of the proposed range, Stemline Therapeutics would command a market value of $128 million. Stemline Therapeutics was founded in 2003. The New York, NY-based company plans to list on the NASDAQ under the symbol STML. RBC Capital Markets and Oppenheimer & Co. are the joint bookrunners on the deal.

Last week, there were 7 IPO pricings. Natural Grocers by Vitamin Cottage (NYSE:NGVC), a western retailer of natural and organic groceries and dietary supplements, was the week's winner, ending up 33% from its IPO price.